Shao Guoliang, Huang Shaolei, Cui Yuying, Yang Dianhui
Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine.
Master of Clinical Integration in Traditional Chinese and Western Medicine, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine.
Medicine (Baltimore). 2020 Nov 25;99(48):e23224. doi: 10.1097/MD.0000000000023224.
Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has been in a public health emergency of international concern since its outbreak in 2020. Due to the complex pathogenesis and susceptibility of COVID-19, many commonly used drugs for the treatment of COVID-19 have not shown excellent clinical effects. Traditional Chinese medicine has a long clinical history of preventing and treating this respiratory infectious disease. Maxingshigan Decoction (MXSG) is widely used in China to treat COVID-19. However, there is no comprehensive and systematic evidence on the effectiveness and safety of Maxingshigan Decoction.
PubMed, EMBASE, Clinical Trials, the Cochrane Library, Sino Med, and China National Knowledge Infrastructure up to September 2020. This study only screens clinical randomized controlled trials on MXSG for COVID-19 to evaluate its efficacy and safety. Data were extracted by 1 investigator and checked by an independent investigator. Review Manager 5.3 software was used for the data analysis. The dichotomous data is represented by relative risk, and the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists.
The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal.
The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Maxingshigan decoction in the treatment of COVID-19.
CRD42020211962.
2019年冠状病毒病（COVID-19）是一种迅速传播的疾病，自2020年爆发以来一直处于国际关注的突发公共卫生事件中。由于COVID-19发病机制复杂且易感性高，许多常用的COVID-19治疗药物并未显示出优异的临床效果。中医在预防和治疗这种呼吸道传染病方面有着悠久的临床历史。麻杏石甘汤在中国被广泛用于治疗COVID-19。然而，关于麻杏石甘汤有效性和安全性的证据并不全面和系统。
检索截至2020年9月的PubMed、EMBASE、临床试验、Cochrane图书馆、中国生物医学文献数据库和中国知网。本研究仅筛选关于麻杏石甘汤治疗COVID-19的临床随机对照试验，以评估其疗效和安全性。数据由1名研究者提取，并由独立研究者进行核对。采用Review Manager 5.3软件进行数据分析。二分数据以相对危险度表示，连续数据以均数差或标准化均数差表示，最终根据是否存在异质性，使用固定效应模型或随机效应模型对数据进行合并。
从确诊阳性到连续2次核酸检测（非同一天）结果为阴性的时间、治愈率。我们的研究结果将发表在同行评议的期刊上。
本系统评价的目的是为麻杏石甘汤治疗COVID-19的有效性和安全性提供新的证据。
PROSPERO注册号：CRD42020211962。
